Literature DB >> 25572477

Adoptive cell therapy for sarcoma.

Melinda Mata1, Stephen Gottschalk.   

Abstract

Current therapy for sarcomas, though effective in treating local disease, is often ineffective for patients with recurrent or metastatic disease. To improve outcomes, novel approaches are needed and cell therapy has the potential to meet this need since it does not rely on the cytotoxic mechanisms of conventional therapies. The recent successes of T-cell therapies for hematological malignancies have led to renewed interest in exploring cell therapies for solid tumors such as sarcomas. In this review, we will discuss current cell therapies for sarcoma with special emphasis on genetic approaches to improve the effector function of adoptively transferred cells.

Entities:  

Keywords:  cancer immunotherapy; cell therapy; gene transfer; sarcoma

Mesh:

Year:  2015        PMID: 25572477      PMCID: PMC4331182          DOI: 10.2217/imt.14.98

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  160 in total

1.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

2.  Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

Authors:  Ling Zhang; Sid P Kerkar; Zhiya Yu; Zhili Zheng; Shicheng Yang; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

3.  Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

Authors:  Gianpietro Dotti; Barbara Savoldo; Martin Pule; Karin C Straathof; Ettore Biagi; Eric Yvon; Stephane Vigouroux; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

4.  Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Authors:  Evripidis Lanitis; Mathilde Poussin; Alex W Klattenhoff; Degang Song; Raphael Sandaltzopoulos; Carl H June; Daniel J Powell
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

5.  Programmed cell death ligand 1 expression in osteosarcoma.

Authors:  Jacson K Shen; Gregory M Cote; Edwin Choy; Pei Yang; David Harmon; Joseph Schwab; G Petur Nielsen; Ivan Chebib; Soldano Ferrone; Xinhui Wang; Yangyang Wang; Henry Mankin; Francis J Hornicek; Zhenfeng Duan
Journal:  Cancer Immunol Res       Date:  2014-04-21       Impact factor: 11.151

6.  IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway.

Authors:  Zhaoxu Li; Qiang Xu; Huiqin Peng; Ruilin Cheng; Zhengwang Sun; Zhaoming Ye
Journal:  Int Immunopharmacol       Date:  2011-01-14       Impact factor: 4.932

7.  Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype.

Authors:  Y Xie; B Skytting; G Nilsson; B Brodin; O Larsson
Journal:  Cancer Res       Date:  1999-08-01       Impact factor: 12.701

8.  Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.

Authors:  Dagmar Berghuis; Susy J Santos; Hans J Baelde; Antonie Hm Taminiau; R Maarten Egeler; Marco W Schilham; Pancras Cw Hogendoorn; Arjan C Lankester
Journal:  J Pathol       Date:  2010-12-10       Impact factor: 7.996

9.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Authors:  Hollie J Pegram; James C Lee; Erik G Hayman; Gavin H Imperato; Thomas F Tedder; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

Review 10.  Bone tumors in adolescents and young adults.

Authors:  Stefan S Bielack; Dorothe Carrle; Jendrik Hardes; Andreas Schuck; Michael Paulussen
Journal:  Curr Treat Options Oncol       Date:  2008-05-01
View more
  5 in total

Review 1.  Current status of engineered T-cell therapy for synovial sarcoma.

Authors:  Matthew Dallos; William D Tap; Sandra P D'Angelo
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196

2.  TJP1 Contributes to Tumor Progression through Supporting Cell-Cell Aggregation and Communicating with Tumor Microenvironment in Leiomyosarcoma.

Authors:  Eun-Young Lee; Minjeong Kim; Beom K Choi; Dae Hong Kim; Inho Choi; Hye Jin You
Journal:  Mol Cells       Date:  2021-11-30       Impact factor: 5.034

Review 3.  Turning 'Cold' tumors 'Hot': immunotherapies in sarcoma.

Authors:  Jeff Rytlewski; Mohammed M Milhem; Varun Monga
Journal:  Ann Transl Med       Date:  2021-06

4.  Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update.

Authors:  Christopher DeRenzo; Stephen Gottschalk
Journal:  J Clin Cell Immunol       Date:  2016-04-29

Review 5.  T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.

Authors:  Zhan Wang; Binghao Li; Yingqing Ren; Zhaoming Ye
Journal:  Front Immunol       Date:  2016-09-14       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.